Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert F Lobuglio

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|January 8, 2004
History of antibody therapy for non-Hodgkin's lymphomaAndres Forero, Albert F Lobuglio
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Invited commentary: targeting of 125I-labeled B lymphocyte stimulatorDonald J Buchsbaum, Albert F LoBuglio
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicityFrancisco Robert, Elizabeth M Busby, Albert F LoBuglio
Future Oncology (London, England)|August 23, 2006
TRAIL receptor-targeted therapyDonald J Buchsbaum, Tong Zhou, Albert F Lobuglio
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancerRuby F Meredith, Donald J Buchsbaum, Ronald D Alvarez, et al.
Cancer Research|September 19, 2012
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairSomaira Nowsheen, Tiffiny Cooper, James A Bonner, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 28, 2002
A non-invasive approach for monitoring breast tumor cells during therapeutic interventionTandra R Chaudhuri, Zhihong Cao, Cristina Rodríguez-Burford, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|January 8, 2004
History of antibody therapy for non-Hodgkin's lymphomaAndres Forero, Albert F Lobuglio
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Invited commentary: targeting of 125I-labeled B lymphocyte stimulatorDonald J Buchsbaum, Albert F LoBuglio
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicityFrancisco Robert, Elizabeth M Busby, Albert F LoBuglio
Future Oncology (London, England)|August 23, 2006
TRAIL receptor-targeted therapyDonald J Buchsbaum, Tong Zhou, Albert F Lobuglio
Future Oncology (London, England)|July 31, 2007
TRAIL-receptor antibodies as a potential cancer treatmentDonald J Buchsbaum, Andres Forero-Torres, Albert F LoBuglio
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2011
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinomaSui Shen, Andres Forero, Ruby F Meredith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancerRuby F Meredith, Donald J Buchsbaum, Ronald D Alvarez, et al.
Cancer Research|September 19, 2012
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairSomaira Nowsheen, Tiffiny Cooper, James A Bonner, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 28, 2002
A non-invasive approach for monitoring breast tumor cells during therapeutic interventionTandra R Chaudhuri, Zhihong Cao, Cristina Rodríguez-Burford, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Pageof 6